Abstracts tagged "SLE"

Abstract Number: 13 • 2015 ACR/ARHP Annual Meeting
Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris³, Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge¹, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J Wallace⁷, David R. Karp⁸, Kathy L. Sivils⁹, John B. Harley¹⁰ and Judith A. James¹¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Aurora, CO, ⁴Medicine, Medical University of South Carolina, Charleston, SC, ⁵Department of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Blood relatives (Rel) of lupus patients have increased risk of SLE. Some have autoantibodies and SLE clinical features, but do not meet ≥ 4…
Abstract Number: 749 • 2015 ACR/ARHP Annual Meeting
Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus
Fariborz Mobarrez¹, Håkan Wallén², Iva Gunnarsson³, Johanna Gustafsson⁴, Agneta Zickert³, David Pisetsky^5,6 and Elisabet Svenungsson⁴, ¹Department of Medicine, Karolinska Institutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ²Division of Cardiovascular Medicine, Karolinska Institutet, Department of Clinical Sciences, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Insitutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Medical Research Service, Durham VA Hospital, Durham, NC, ⁶Department of Medicine, Duke University Medical Center,, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes of antinuclear antibodies. As a source of these antigens, increased levels…
Abstract Number: 1069 • 2015 ACR/ARHP Annual Meeting
Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity
Giovanna I. Cruz¹, Xiaorong Shao², Hong L. Quach², Janelle Noble³, Nikolaos Patsopoulos⁴, Michael Busch⁵, Darrell Triulzi⁶, Wendy S.W. Wong⁷, Benjamin Solomon⁷, John Niederhuber⁷, Lindsey A. Criswell⁸ and Lisa F. Barcellos², ¹School of Public Health, University of California, Berkeley, Berkeley, CA, ²Genetic Epidemiology and Genomics Laboratory, University of California, Berkeley, Berkeley, CA, ³Children's Hospital Oakland Research Institute, Oakland, CA, ⁴Division of Genetics, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ⁵Blood Systems Research Institute, San Francisco, CA, ⁶Institute of Transfusion Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Medical Genomics, Inova Translational Medicine Institute, Falls Church, VA, ⁸Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: SLE [MIM 152700] disproportionately affects women of reproductive age and pregnant patients are more likely to experience flares. Fetal microchimerism (FMC), or the persistence…
Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Eoghan M. McCarthy^1,2, Emily Sutton³, David A. Isenberg⁴, Anisur Rahman⁴, Benjamin Rhodes⁵, Peter Hewins⁶, Neil J McHugh⁷, Ben Parker⁸, Bridget Griffiths⁹, Peter Lanyon¹⁰, Edward M. Vital¹¹, Lee-Suan Teh¹², Mohammed Akil¹³, Hazem Youssef¹⁴, David P. D'Cruz¹⁵, Munther Khamashta¹⁶, Nicola Erb¹⁷, David Jayne¹⁸, Christopher J. Edwards¹⁹, Athiveer Prabu²⁰, Michael Batley²¹, Nagui Gendi²², Bhaskar Dasgupta^23,24, Richard J. Stratton²⁵, Chee-Seng Yee²⁶, Asad Zoma²⁷, Caroline Gordon²⁸, Antoni Chan²⁹, Steven Young Min³⁰, Shirish Dubey³¹, Jon King³², Denise De Lord³³, Edmond O'Riordan³⁴, Rachel Jeffery³⁵, Waji Hassan³⁶, Marian Regan³⁷ and Ian N. Bruce³⁸, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ²The University of Manchester, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Mmanchester, United Kingdom, ³University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, England, ⁵Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁶Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁷Rheumatology, Bath Institute of Rheumatic Diseases, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁹Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁰Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹²Department of Rheumatology, Royal Blackburn Hospital, Blackburn, United Kingdom, ¹³Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, ¹⁴Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ¹⁵Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ¹⁶Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ¹⁷Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom, ¹⁸Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom, ¹⁹University Hospital Southampton, Southampton, United Kingdom, ²⁰Worcester Royal Hospital, Worcester, Worcester, United Kingdom, ²¹Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom, ²²Rheumatology, Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, ²³Southend University Hospital, Southend, United Kingdom, ²⁴Rheumatology, Southend University Hospital, Essex, United Kingdom, ²⁵Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ²⁶Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ²⁷Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²⁸Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²⁹Rheumatology, Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ³⁰Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom, ³¹Rheumatology, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³²Rheumatology, Derriford Hospital, Plymouth, United Kingdom, ³³Rheumatology, Queen Elizabeth the Queen Mother Hospital, East Kent, United Kingdom, ³⁴Renal Medicine, Salford Royal Foundation Trust, Manchester, United Kingdom, ³⁵Rheumatology, Northampton General Hospital, Northampton, United Kingdom, ³⁶Rheumatology, University Hospitals of Leicester, Leicester, United Kingdom, ³⁷Rheumatology, Royal Derby Hospital, Derby, United Kingdom, ³⁸Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…
Abstract Number: 2067 • 2015 ACR/ARHP Annual Meeting
De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus
S Bandyopadhyay¹, SE Connolly¹, O Jabado¹, S Kelly¹, M Maldonado¹, R Westhovens², P Nash³, JT Merrill⁴ and R Townsend¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University Hospitals KU Leuven, Leuven, Belgium, ³University of Queensland, Brisbane, Australia, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Phase IIb IM101-042 trial was a randomized, double-blind, placebo-controlled trial of abatacept (ABA) in systemic lupus erythematosus patients (pts) with polyarthritis, discoid lesions…
Abstract Number: 3081 • 2015 ACR/ARHP Annual Meeting
IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8
Carla M. Cuda¹ and Harris R. Perlman², ¹Rheumatology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…
Abstract Number: 56 • 2015 ACR/ARHP Annual Meeting
Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)
Kathryn Jackson, Theresa Walunas, Anh Chung and Rosalind Ramsey-Goldman, Northwestern University, Chicago, IL
Background/Purpose: Care fragmentation is associated with poor health outcomes and is hard to assess in a single-site data registry. The Chicago HealthLNK Data Repository (CHDR)…
Abstract Number: 753 • 2015 ACR/ARHP Annual Meeting
Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy
Jakub Zavada¹, Michal Uher², Radka Svobodova³, Marta Olejarova¹, Marketa Husakova³, Hana Ciferska³, Hana Hulejova⁴, Ladislav Senolt³ and Jiri Vencovsky³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic
Background/Purpose: The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TSC) are useful as an activity-specific or predictive…
Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting
CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Sarit sekhar Pattanaik¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…
Abstract Number: 1801 • 2015 ACR/ARHP Annual Meeting
Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice
Syed Mahmood Shah, Michelle Petri and Hendrik Scholl, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The risk of end-stage retinopathy (bull’s eye maculopathy) from hydroxychloroquine (HCQ) is low (0.65%, Wolfe and Marmor, 2010). With recent advances in retinal structure…
Abstract Number: 2071 • 2015 ACR/ARHP Annual Meeting
Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study
Ranjan Gupta¹, Amita Aggarwal², Sudhir sinha³, Liza Rajasekhar⁴, Akhilesh Yadav¹, Priyanka Gaur¹, Ramnath Misra² and Virsingh Negi⁵, ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, ⁴Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, ⁵Department of Clinical Immunology, JIPMER, Puducherry, India
Background/Purpose: Urinary biomarkers may help in identification, treatment and assessment of response to therapy in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by…
Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting
Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Tianfu Wu¹, Huihua Ding², Cristina Arriens³, Chungwen Wei⁴, Jennifer H. Anolik⁵, David R. Karp³, Nancy J. Olsen⁶, Michelle Petri⁷, Ignacio Sanz⁴, Ramesh Saxena⁸ and Chandra Mohan², ¹Department of Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁸Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
Abstract Number: 88 • 2015 ACR/ARHP Annual Meeting
Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans
Paula S. Ramos¹, Satria Sajuthi², Jasmin Divers³, Kenneth M. Kaufman⁴, Uma Nayak⁵, Wei-Min Chen⁵, Kelly J. Hunt⁶, Diane L. Kamen⁷, Gary S. Gilkeson⁸, Jyotika K. Fernandes⁷, Ida J. Spruill⁹, Robert P. Kimberly¹⁰, John B. Harley¹¹, W. Timothy Garvey¹², Michèle M. Sale¹³ and Carl D. Langefeld², ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Public Health Sciences, University of Virginia, Charlottesville, VA, ⁶Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁷Medicine, Medical University of South Carolina, Charleston, SC, ⁸Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Nursing, Medical University of South Carolina, Charleston, SC, ¹⁰Medicine, Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹²Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL, ¹³Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA
Background/Purpose: In many rheumatologic and autoimmune diseases African Americans (AA) have a higher prevalence and greater disease severity than other ethnicities. We posit that population-specific…
Abstract Number: 758 • 2015 ACR/ARHP Annual Meeting
Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic
Laura Geraldino-Pardilla¹, Ivonne Canto², Thania Perez³, Jossiell Then², Esthela Loyo⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, ³Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, ⁵Department of Medicine Rhemuatology, Colombia University, New York, NY
Background/Purpose: Higher accrual of damage has been reported in Hispanics with systemic lupus erythematosus (SLE) in the United States. This study was initiated to evaluate…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].